BIOLASE (BIOL) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock BIOL vs. AFIB, GMVDF, VRAYQ, NMRD, VIVE, UTRS, MOTS, DRTSW, ANZUW, and ATAKWShould you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include Acutus Medical (AFIB), G Medical Innovations (GMVDF), ViewRay (VRAYQ), Nemaura Medical (NMRD), Viveve Medical (VIVE), Minerva Surgical (UTRS), Motus GI (MOTS), Alpha Tau Medical (DRTSW), Anzu Special Acquisition Corp I (ANZUW), and Aurora Technology Acquisition (ATAKW). These companies are all part of the "medical equipment" industry. BIOLASE vs. Its Competitors Acutus Medical G Medical Innovations ViewRay Nemaura Medical Viveve Medical Minerva Surgical Motus GI Alpha Tau Medical Anzu Special Acquisition Corp I Aurora Technology Acquisition Acutus Medical (NASDAQ:AFIB) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations. Is AFIB or BIOL more profitable? BIOLASE has a net margin of -41.65% compared to Acutus Medical's net margin of -272.74%. Acutus Medical's return on equity of -311.64% beat BIOLASE's return on equity.Company Net Margins Return on Equity Return on Assets Acutus Medical-272.74% -311.64% -11.57% BIOLASE -41.65%-1,782.73%-55.31% Do institutionals & insiders hold more shares of AFIB or BIOL? 56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, AFIB or BIOL? Acutus Medical has a beta of -0.67, suggesting that its stock price is 167% less volatile than the S&P 500. Comparatively, BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Which has higher valuation & earnings, AFIB or BIOL? BIOLASE has higher revenue and earnings than Acutus Medical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcutus Medical$7.16M0.00-$81.66MN/AN/ABIOLASE$48.83M0.00-$20.63M-$14.94N/A Does the media prefer AFIB or BIOL? In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score. Company Overall Sentiment Acutus Medical Neutral BIOLASE Neutral SummaryAcutus Medical and BIOLASE tied by winning 4 of the 8 factors compared between the two stocks. Get BIOLASE News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOL vs. The Competition Export to ExcelMetricBIOLASEDental equipment & supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$581K$84.50K$9.05B$10.60BDividend YieldN/AN/A5.69%4.71%P/E Ratio0.00N/A85.8527.35Price / SalesN/A0.00535.75201.60Price / CashN/AN/A37.9261.55Price / BookN/A0.0013.056.78Net Income-$20.63M-$73.66M$3.30B$275.79M BIOLASE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOLBIOLASEN/AN/AN/AN/A$581K$48.83M0.00160AFIBAcutus MedicalN/A$0.00flatN/A-99.5%$27K$7.16M0.00340GMVDFG Medical InnovationsN/A$0.00flatN/AN/A$26K$4.42M0.0072VRAYQViewRayN/AN/AN/AN/A$18K$102.21M0.00300High Trading VolumeNMRDNemaura Medical0.7575 of 5 starsN/AN/A-99.4%$4K$3.02K0.0040VIVEViveve MedicalN/A$0.00flatN/A-75.0%$2K$6.83M0.0070Gap DownUTRSMinerva SurgicalN/A$0.00flatN/AN/A$1K$51.69M0.00160High Trading VolumeMOTSMotus GI0.0656 of 5 starsN/AN/A-99.7%$1K$319K0.0030DRTSWAlpha Tau MedicalN/A$0.35-2.9%N/A+94.1%$0.00N/A0.0080Positive NewsANZUWAnzu Special Acquisition Corp IN/A$0.03+0.6%N/AN/A$0.00N/A0.002Gap UpATAKWAurora Technology AcquisitionN/A$0.02+19.6%N/A-70.0%$0.00N/A0.00N/AGap Up Related Companies and Tools Related Companies Acutus Medical Alternatives G Medical Innovations Alternatives ViewRay Alternatives Nemaura Medical Alternatives Viveve Medical Alternatives Minerva Surgical Alternatives Motus GI Alternatives Alpha Tau Medical Alternatives Anzu Special Acquisition Corp I Alternatives Aurora Technology Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOL) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BIOLASE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
